GSK - Ticker AI Digest

GSK 16:55

GSK plc

Blujepa approved in US for gonorrhoea indication

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced on December 11, 2025, that the U.S. Food and Drug Administration (FDA) has approved **Blujepa (gepotidacin)**, a first-in-class oral antibiotic, for the treatment of **uncomplicated urogenital gonorrhoea (uGC)** in adults and adolescents aged 12 and older weighing at least 45 kg. This approval marks the first new antibiotic class for gonorrhoea in over three decades, offering a much-needed alternative to injectable treatments.

**Key Highlights**

**Innovation** Blujepa is the first new class of antibiotics for gonorrhoea since 1987, addressing the urgent need for new treatments due to rising antimicrobial resistance.

**Indication** Approved for patients with limited or no alternative treatment options, such as those intolerant to or unwilling to use first-line injectable therapies.

**Clinical Evidence** Positive results from the **EAGLE-1 Phase III trial** demonstrated non-inferiority to the standard of care (ceftriaxone + azithromycin) with a favorable safety profile.

**Public Health Impact** Gonorrhoea, caused by *Neisseria gonorrhoeae*, is a priority pathogen for the WHO and an urgent public health threat in the U.S., with over 600,000 cases reported in 2023.

**Mechanism** Gepotidacin inhibits bacterial DNA replication through a novel mechanism, providing activity against resistant strains.

**Funding** Development was partially funded by the U.S. Department of Health and Human Services and the Department of Defense.

This approval underscores GSK’s commitment to addressing infectious diseases and combating antimicrobial resistance (AMR), with gepotidacin also approved earlier in 2025 for uncomplicated urinary tract infections (uUTI).

**Media and Investor Contacts**

GSK provided contact details for media and investor relations inquiries, emphasizing the significance of this milestone in infectious disease treatment.

Go Back To AI Charts

GSK 16:55

GSK plc

Blujepa approved in US for gonorrhoea indication

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced on December 11, 2025, that the U.S. Food and Drug Administration (FDA) has approved **Blujepa (gepotidacin)**, a first-in-class oral antibiotic, for the treatment of **uncomplicated urogenital gonorrhoea (uGC)** in adults and adolescents aged 12 and older weighing at least 45 kg. This approval marks the first new antibiotic class for gonorrhoea in over three decades, offering a much-needed alternative to injectable treatments.

**Key Highlights**

**Innovation** Blujepa is the first new class of antibiotics for gonorrhoea since 1987, addressing the urgent need for new treatments due to rising antimicrobial resistance.

**Indication** Approved for patients with limited or no alternative treatment options, such as those intolerant to or unwilling to use first-line injectable therapies.

**Clinical Evidence** Positive results from the **EAGLE-1 Phase III trial** demonstrated non-inferiority to the standard of care (ceftriaxone + azithromycin) with a favorable safety profile.

**Public Health Impact** Gonorrhoea, caused by *Neisseria gonorrhoeae*, is a priority pathogen for the WHO and an urgent public health threat in the U.S., with over 600,000 cases reported in 2023.

**Mechanism** Gepotidacin inhibits bacterial DNA replication through a novel mechanism, providing activity against resistant strains.

**Funding** Development was partially funded by the U.S. Department of Health and Human Services and the Department of Defense.

This approval underscores GSK’s commitment to addressing infectious diseases and combating antimicrobial resistance (AMR), with gepotidacin also approved earlier in 2025 for uncomplicated urinary tract infections (uUTI).

**Media and Investor Contacts**

GSK provided contact details for media and investor relations inquiries, emphasizing the significance of this milestone in infectious disease treatment.

Go Back To AI Charts

GSK 06:01

GSK plc

GSK'227 US FDA Orphan Drug Designation in SCLC

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSK plc announced that its investigational antibody-drug conjugate, risvutatug rezetecan (GSK227), has received Orphan Drug Designation (ODD) from the US FDA for treating small-cell lung cancer (SCLC). This designation is supported by early clinical data showing durable responses in patients with extensive-stage SCLC (ES-SCLC), a particularly aggressive form of the disease with limited treatment options and poor prognosis.

Risvutatug rezetecan targets B7-H3, a protein overexpressed in various solid tumors, and is being developed for multiple cancer types, including lung, prostate, and colorectal cancers. This ODD marks the fifth regulatory designation for the drug, highlighting its potential as a transformative treatment. GSK has initiated a global Phase III trial for risvutatug rezetecan in relapsed ES-SCLC, further accelerating its development.

SCLC accounts for approximately 13% of all lung cancers in the US, with an estimated 29,500 new cases in 2025. ES-SCLC, representing 70% of SCLC cases, has a 5-year survival rate of only 3%, underscoring the urgent need for effective therapies. GSK’s progress with risvutatug rezetecan offers hope for patients with this challenging disease.

Go Back To AI Charts

GSK 06:01

GSK plc

Initiation of litigation against AnaptysBio Inc

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc’s subsidiary, TESARO, Inc., has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court, alleging material breach of their license agreement for the oncology treatment Jemperli (dostarlimab). TESARO claims AnaptysBio’s recent conduct justifies terminating the agreement, obtaining a perpetual license for dostarlimab, and reducing royalties and milestone payments by 50%. This move follows AnaptysBio’s allegations that TESARO failed to meet certain requirements of the 2014 license agreement, which GSK and TESARO dismiss as meritless. Jemperli, approved in over 35 countries for endometrial cancer, has seen significant growth, and GSK is advancing clinical trials to explore its use in additional cancers. The litigation underscores a dispute over the rights and obligations under the license agreement, with potential implications for the future of dostarlimab’s development and commercialization.

Go Back To AI Charts

GSK 16:55

GSK plc

Blujepa approved in US for gonorrhoea indication

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced on December 11, 2025, that the U.S. Food and Drug Administration (FDA) has approved **Blujepa (gepotidacin)**, a first-in-class oral antibiotic, for the treatment of **uncomplicated urogenital gonorrhoea (uGC)** in adults and adolescents aged 12 and older weighing at least 45 kg. This approval marks the first new antibiotic class for gonorrhoea in over three decades, offering a much-needed alternative to injectable treatments.

**Key Highlights**

**Innovation** Blujepa is the first new class of antibiotics for gonorrhoea since 1987, addressing the urgent need for new treatments due to rising antimicrobial resistance.

**Indication** Approved for patients with limited or no alternative treatment options, such as those intolerant to or unwilling to use first-line injectable therapies.

**Clinical Evidence** Positive results from the **EAGLE-1 Phase III trial** demonstrated non-inferiority to the standard of care (ceftriaxone + azithromycin) with a favorable safety profile.

**Public Health Impact** Gonorrhoea, caused by *Neisseria gonorrhoeae*, is a priority pathogen for the WHO and an urgent public health threat in the U.S., with over 600,000 cases reported in 2023.

**Mechanism** Gepotidacin inhibits bacterial DNA replication through a novel mechanism, providing activity against resistant strains.

**Funding** Development was partially funded by the U.S. Department of Health and Human Services and the Department of Defense.

This approval underscores GSK’s commitment to addressing infectious diseases and combating antimicrobial resistance (AMR), with gepotidacin also approved earlier in 2025 for uncomplicated urinary tract infections (uUTI).

**Media and Investor Contacts**

GSK provided contact details for media and investor relations inquiries, emphasizing the significance of this milestone in infectious disease treatment.

Go Back To AI Charts

GSK 06:01

GSK plc

GSK'227 US FDA Orphan Drug Designation in SCLC

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSK plc announced that its investigational antibody-drug conjugate, risvutatug rezetecan (GSK227), has received Orphan Drug Designation (ODD) from the US FDA for treating small-cell lung cancer (SCLC). This designation is supported by early clinical data showing durable responses in patients with extensive-stage SCLC (ES-SCLC), a particularly aggressive form of the disease with limited treatment options and poor prognosis.

Risvutatug rezetecan targets B7-H3, a protein overexpressed in various solid tumors, and is being developed for multiple cancer types, including lung, prostate, and colorectal cancers. This ODD marks the fifth regulatory designation for the drug, highlighting its potential as a transformative treatment. GSK has initiated a global Phase III trial for risvutatug rezetecan in relapsed ES-SCLC, further accelerating its development.

SCLC accounts for approximately 13% of all lung cancers in the US, with an estimated 29,500 new cases in 2025. ES-SCLC, representing 70% of SCLC cases, has a 5-year survival rate of only 3%, underscoring the urgent need for effective therapies. GSK’s progress with risvutatug rezetecan offers hope for patients with this challenging disease.

Go Back To AI Charts

GSK 06:01

GSK plc

Initiation of litigation against AnaptysBio Inc

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc’s subsidiary, TESARO, Inc., has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court, alleging material breach of their license agreement for the oncology treatment Jemperli (dostarlimab). TESARO claims AnaptysBio’s recent conduct justifies terminating the agreement, obtaining a perpetual license for dostarlimab, and reducing royalties and milestone payments by 50%. This move follows AnaptysBio’s allegations that TESARO failed to meet certain requirements of the 2014 license agreement, which GSK and TESARO dismiss as meritless. Jemperli, approved in over 35 countries for endometrial cancer, has seen significant growth, and GSK is advancing clinical trials to explore its use in additional cancers. The litigation underscores a dispute over the rights and obligations under the license agreement, with potential implications for the future of dostarlimab’s development and commercialization.

Go Back To AI Charts